Commit: Activating the complement pathway to deeply deplete target cells

Commit is aiming for deep depletion of target cells by activating the most upstream component in the classical complement pathway using bispecific single-domain antibodies. The approach offers a new way to kill autoreactive or cancerous B cells that could compete with CAR T cell and bispecific T cell-engager therapies.

Commit’s technology comes from Denmark’s Aarhus University, considered a center of excellence in complement biology, CEO Krishna Polu told BioCentury. “They’ve been collaborating with pharma and biotech in the complement therapeutics field for a long time.”...